Clinical trial NCT02325570: Evaluation of the KLOX BioPhotonic OraLum Gel With a LED Curing Lamp in Moderate to Severe Chronic Periodontitis
Official title: The Evaluation of the Clinical Effects of the KLOX BioPhotonic OraLum Gel With a LED Curing Lamp as an Adjunct to the Non-Surgical Treatment of Moderate to Severe Chronic Periodontitis
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Moderate to Severe Chronic Periodontitis
Lead sponsor: KLOX Technologies Inc.
Sponsor class: INDUSTRY
First posted: 2014-12-25
Enrollment: 30
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Multicenter, prospective, interventional open case series study using a randomized split-mouth design in moderate to severe chronic periodontitis patients having half-mouth treated with the KLOX BioPhotonic OraLum gel with a LED curing lamp as an adjunct to conventional non-surgical periodontal treatment (SRP) versus SRP alone in the second (control) half-mouth.


Eligibility criteria: Inclusion Criteria:

1. Signed and dated written informed consent form;
2. Male or female patients aged 18 years old and above;
3. Good general health, free of systemic diseases such as diabetes, arthritis, HIV infection or genetic disorder that could influence the outcome of the treatment;
4. Patient with clinically confirmed signs and symptoms of generalized moderate to severe chronic periodontitis (as defined according to International Classification of Periodontal Diseases, Armitage 1999);
5. Patient has had no periodontal treatment for the last year prior to the study;
6. Females of childbearing potential must not be pregnant nor lactating at study entry and agree to use an adequate contraceptive method during the study.

   Inclusion Criteria Post Oral Hygiene Instructions (OHI):
7. Patient demonstrates sufficient plaque control as indicated by a plaque score \< 30% after hygiene period;
8. Patient has at least two sites in each quadrant with probing pocket depth (PPD) equal or more than 5 mm or equal or less than 7 mm.

Exclusion Criteria:

1. Patient with an existing aggressive periodontitis;
2. Presence of oral local mechanical factor(s) that could, in the opinion of the investigator, influence the outcome of the study;
3. Presence of orthodontic appliances, or any removable appliances, that impinges on the tissues being assessed;
4. Soft or hard tissue tumours of the oral cavity;
5. Systemic antibiotic therapy or anti-inflammatory drugs or any other medication(s) that might interfere with periodontal healing within the last three months prior to study entry and throughout the study duration;
6. Patient has participated in any other clinical study within 30 days prior to study entry and throughout the study duration;
7. Use of anticoagulants such as warfarin, clopidogrel, enoxaparin or high doses of aspirin (162 mg daily);
8. Regular use of chlorhexidine oral rinses / mouthwashes (Non-medicated, over the counter, mouthwashes are acceptable);
9. Patient with current alcohol abuse or actively consuming drugs (addiction); as it may interfere with patient's ability to comply with study procedures
10. Periodontal surgery planned during the study;
11. Female patient pregnant, nursing or planning to become pregnant within the next 12 months;
12. Patient is a current smoker or had been smoking or using nicotine product(s) in the last six months;
13. Concurrent disease (such as porphyria) or drug(s) (such as methotrexate or chloroquine) known to induce severe photosensitivity of the skin;
14. Patient has ongoing malignant disease of any type, or any significant chronic disease which, in the opinion of the investigator, might interfere with the evaluation of the study objectives or would result in non-compliance with the study protocol;
15. Patients with known hypersensitivity to peroxide;
16. Patients with known photosensitivity or who take drugs to treat photosensitivity.

Primary outcomes:
measure: Adverse events, Serious adverse events and incidents
timeFrame: 3 weeks
measure: Ease of performing SRP and time required to perform SRP
timeFrame: 2 weeks
Secondary outcomes:
measure: Impact on tissues (Visual examination of tissues)
timeFrame: 3 weeks
measure: Impact on bleeding (Use of Bleeding on Probing (BOP) results)
timeFrame: 2 weeks
measure: Impact on Plaque Index (PI)
timeFrame: 2 weeks
measure: Impact on Gingival index (GI)
timeFrame: 2 weeks
measure: Pain (Visual Analog Scale)
timeFrame: 2 weeks
Other outcomes:
measure: Exploratory endpoint: patient's preference questionnaire
timeFrame: 2 weeks
Locations:
city: Montreal
country: Canada
facility: Dr. Anthony Seminara Inc.
state: Quebec
Study officials:
affiliation: Dr. Anthony Seminara Inc.
name: Anthony Seminara, DDM
role: PRINCIPAL_INVESTIGATOR
References: